Invitrogen

Fc Receptor Binding Inhibitor Polyclonal Antibody, eBioscience™

Fc Receptor Binding Inhibitor Antibody in Flow Cytometry (Flow)

FIGURE: 1 / 1

Fc Receptor Binding Inhibitor Antibody (14-9162-42) in Flow

Normal canine peripheral blood cells were unstained (orange histogram), stained with Rat IgG2b K Isotype Control FITC (Product # 11-4031-82) (blue histogram), or were pretreated with Canine Fc Receptor Binding Inhibitor Purified and then stained with Rat IgG2b K Isotype Control FITC (purple histogram).Cells in the monocyte gate were used for analysis.

Product Image Gallery

Product Details

14-9162-42

Applications

Tested Dilution

Publications

Flow Cytometry (Flow)

5 µL (10 µg)/test

View 5 publications 5 publications

Product Specifications

Species Reactivity

Dog

Published species

Dog

Class

Polyclonal

Type

Antibody

Conjugate

Unconjugated Unconjugated Unconjugated

Form

Liquid

Concentration

5 µL/Test

Purification

Affinity chromatography

Storage buffer

PBS, pH 7.2, with BSA

Contains

0.09% sodium azide

Storage conditions

4° C

Shipping conditions

Ambient (domestic); Wet ice (international)

RRID

AB_2572935

Product Specific Information

Description: The Canine Fc Receptor Binding Inhibitor can be used to inhibit the non-specific Fc receptor (FcR)-mediated binding of rat monoclonal antibodies used for flow cytometric analysis of canine tissue. FcR are expressed at varying levels in multiple cell lineages including high expression in myeloid cells, granulocytes, and B cells. The biological function of the FcR, including initiation of endocytosis, phagocytosis, and antigen presentation, is elicited upon binding of host-immunoglobulin. The extent to which rat monoclonal antibodies will bind to canine FcR varies depending on the isotype of the monoclonal antibody.

eBioscience testing indicates that rat IgG2b isotype is blocked by Canine Fc Receptor Binding Inhibitor.

Applications Reported: Canine Fc Receptor Binding Inhibitor Purified has been reported for use in flow cytometric analysis.

To inhibit the non-specific binding of rat monoclonal antibodies add the canine Fc Receptor Binding Inhibitor to samples and incubate on ice for 20 minutes. Without washing, proceed to stain with primary antibody.

Applications Tested: Canine Fc Receptor Binding Inhibitor Purified has been pre-titrated and tested by flow cytometric analysis on canine peripheral blood cells. This can be used at 5 µL (10 µg) per test. A test is defined as the amount (µg) of antibody that will stain a cell sample in a final volume of 100 µL. Cell number should be determined empirically but can range from 10^5 to 10^8 cells/test.

Purity: Greater than 90%, as determined by SDS-PAGE.

Aggregation: Less than 10%, as determined by HPLC.

Filtration: 0.2 µm post-manufacturing filtered.

Target Information

Four different classes of Fcy receptors have been identified: FcyRI (CD64), FcyRII (CD32), and FcyRIII (CD16), and they are expressed at varying levels in multiple cell lineages including high expression in myeloid, granulocyte and B cells. The biological function of the FcyR, including initiation of endocytosis, phagocytosis and antigen presentation, is elicited upon binding of host-immunoglobulin. The extent to which mouse monoclonal antibodies will bind to human FcyR varies depending on the isotype of the monoclonal antibody. Furthermore, different monoclonal antibodies of the same isotype will display different binding to human FcyRs.

For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization.

Product References

Evaluation of tumor immunity after administration of conditionally replicative adenoviral vector in canine osteosarcoma patients.

Heliyon

Agarwal P,Gammon EA,Sandey M,Lindley SS,Koehler JW,Matz BM,Smith AN,Kashentseva EA,Dmitriev IP,Curiel DT,Smith BF

14-9162-42 was used in Flow Cytometry to propose that OC-CAVE1 (CAV2 with the E1A promoter replaced with the osteocalcin promotor) may also enhance existing immunity against tumors by overcoming immune tolerance via exposure of new epitopes and cytokine signaling.

Mon Feb 01 00:00:00 EST 2021

Comparative Immunogenomics of Canine Natural Killer Cells as Immunotherapy Target.

Frontiers in immunology

Gingrich AA,Reiter TE,Judge SJ,York D,Yanagisawa M,Razmara A,Sturgill I,Basmaci UN,Brady RV,Stoffel K,Murphy WJ,Rebhun RB,Brown CT,Canter RJ

14-9162-42 was used in Flow Cytometry to define canine NK cell gene expression under multiple conditions and across species, filling an important gap in translational NK studies.

Wed Sep 27 00:00:00 EDT 2023

Analysis of tumor-infiltrating NK and T cells highlights IL-15 stimulation and TIGIT blockade as a combination immunotherapy strategy for soft tissue sarcomas.

Journal for immunotherapy of cancer

Judge SJ,Darrow MA,Thorpe SW,Gingrich AA,O'Donnell EF,Bellini AR,Sturgill IR,Vick LV,Dunai C,Stoffel KM,Lyu Y,Chen S,Cho M,Rebhun RB,Monjazeb AM,Murphy WJ,Canter RJ

14-9162 was used in Flow cytometry/Cell sorting to assess the effects of interleukin 15 (IL-15) stimulation on both NK and T cell activation and TIGIT upregulation. Finally, we evaluated cytotoxic effects of IL-15 combined with TIGIT blockade using a novel anti-TIGIT antibody.

Sun Nov 01 00:00:00 EDT 2020

Blood and tissue biomarker analysis in dogs with osteosarcoma treated with palliative radiation and intra-tumoral autologous natural killer cell transfer.

PloS one

Judge SJ,Yanagisawa M,Sturgill IR,Bateni SB,Gingrich AA,Foltz JA,Lee DA,Modiano JF,Monjazeb AM,Culp WTN,Rebhun RB,Murphy WJ,Kent MS,Canter RJ

14-9162-42 was used in Flow Cytometry to report correlative analyses of blood and tissue specimens for signals of immune activation in trial subjects.

Tue May 05 00:00:00 EDT 2020

Radiotherapy enhances natural killer cell cytotoxicity and localization in pre-clinical canine sarcomas and first-in-dog clinical trial.

Journal for immunotherapy of cancer

Canter RJ,Grossenbacher SK,Foltz JA,Sturgill IR,Park JS,Luna JI,Kent MS,Culp WTN,Chen M,Modiano JF,Monjazeb AM,Lee DA,Murphy WJ

14-9162-42 was used in Flow cytometry/Cell sorting to assess radiotherapy (RT) plus local autologous natural killer (NK) transfer in canine sarcomas.

Tue Dec 19 00:00:00 EST 2017

Bioinformatics

Protein Aliases: Fc blocking; FcR BI; FcR Inhibitor

View more View less

Performance Guarantee

If an Invitrogen™ antibody doesn't perform as described on our website or datasheet,we'll replace the product at no cost to you, or provide you with a credit for a future purchase.*

Learn more